[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 25 of about 25
1. Matei DV, Rocco B, Varela R, Verweij F, Scardino E, Renne G, De Cobelli O: Synchronous collecting duct carcinoma and papillary renal cell carcinoma: a case report and review of the literature. Anticancer Res; 2005 Jan-Feb;25(1B):579-86
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous collecting duct carcinoma and papillary renal cell carcinoma: a case report and review of the literature.
  • We herein present a case of collecting duct carcinoma (CDC) combined with papillary renal carcinoma (RCC) having a 57-month disease-free survival CDC is a rather rare and aggressive neoplasm of the kidney.
  • Sharing probably the same embryological origin, synchronous or metachronous association with in situ orpapillary transitional cell carcinoma (TCC) may be found; association with RCC has been only once reported in the literature.
  • The high incidence of c-erbB-2 oncogene amplification in CDC further characterizes this tumor as a separate entity from renal cell carcinoma, and shows some genetic characteristics in common with TCC.
  • The histological diagnosis of Bellini CDC can be confirmed by the positive immunohistochemical staining with a collecting duct marker and distal tubule marker and negative staining with a proximal tubule marker.
  • [MeSH-major] Carcinoma / complications. Carcinoma / diagnosis. Carcinoma, Renal Cell / complications. Carcinoma, Renal Cell / diagnosis. Kidney Neoplasms / diagnosis. Kidney Tubules, Collecting / pathology
  • [MeSH-minor] Aged. Disease-Free Survival. Humans. Immunohistochemistry. Kidney / pathology. Male. Neoplasms, Multiple Primary / diagnosis. Receptor, ErbB-2 / biosynthesis. Time Factors. Tomography, X-Ray Computed


2. Santin AD, Bellone S, Van Stedum S, Bushen W, Palmieri M, Siegel ER, De Las Casas LE, Roman JJ, Burnett A, Pecorelli S: Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma. Cancer; 2005 Oct 1;104(7):1391-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma.
  • BACKGROUND: Overexpression of the epidermal growth factor type II receptor HER-2/neu has been associated with resistance to chemotherapy and poor survival in several human tumors.
  • In the current study, the authors have determined the frequency and clinical significance of HER-2/neu gene amplification in uterine serous papillary endometrial carcinoma (USPC), a highly aggressive variant of endometrial carcinoma.
  • METHODS: Fluorescence in situ hybridization (FISH) assay was used to analyze gene amplification in paraffin blocks from 30 women harboring Stage IA-IV USPC treated at the University of Arkansas for Medical Sciences (Little Rock, AR) from 1997 to 2004.
  • Patients with USPC harboring tumors with HER-2/neu gene amplification had a significantly shorter survival time from diagnosis to disease-related death when compared with FISH-negative patients (P = 0.0008).
  • Determination of HER-2/neu gene amplification may guide clinical management of patients with USPC and may have important implications for the implementation of novel treatment strategies.
  • [MeSH-major] Biomarkers, Tumor / analysis. Cystadenocarcinoma, Papillary / pathology. Gene Amplification. Receptor, ErbB-2 / metabolism. Uterine Neoplasms / pathology
  • [MeSH-minor] Age Factors. Aged. Biopsy, Needle. Female. Gene Expression Regulation, Neoplastic. Genes, erbB-2 / genetics. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Middle Aged. Probability. Prognosis. Risk Assessment. Sampling Studies. Sensitivity and Specificity. Statistics, Nonparametric. Survival Analysis


3. Turrini O, Cano C, Legoffic A, Delpero JR, Dagorn JC, Iovanna J: Genetic alterations in precancerous pancreatic lesions and their clinical implications. Gastroenterol Clin Biol; 2009 Oct-Nov;33(10-11):1028-35, e1-9
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Risk factors associated with the sporadic form of pancreatic adenocarcinoma are unknown and less than 10% of patients receive curative treatment (surgery associated with radiation therapy or chemotherapy) with a low 5-year survival rate (10 to 20%).
  • In more than 90% of patients, the tumor discovered at diagnosis is not resectable or has already metastasized.
  • Thus, a better understanding of the etiology of pancreatic cancer is essential to identify new prognostic markers and new therapeutic targets.
  • This review will focus on the current knowledge of genetic alterations associated with two pancreatic lesions that can potentially evolve into pancreatic adenocarcinoma, Pancreatic Intraepithelial Neoplasia (PanIN) and Intraductal Papillary Mucinous Neoplasm (IPMN).
  • A better understanding of these alterations may lead to therapeutic targets that could help prevent the progression of PanIN and IPMN to cancer.
  • [MeSH-minor] Adenocarcinoma, Mucinous / genetics. Carcinoma in Situ / genetics. Carcinoma, Papillary / genetics. Humans. Proto-Oncogene Proteins / genetics. Telomere / ultrastructure. Tumor Suppressor Proteins / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19766418.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] eng; fre
  • [Publication-type] Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


Advertisement
4. Katusin D, Poka Z, Mlinac-Lucijanić M, Kriz M, Klarić-Vucinić S, Ilijanić J: [Carcinoma in situ in the urinary bladder]. Lijec Vjesn; 2000 Jul-Aug;122(7-8):177-9
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Carcinoma in situ in the urinary bladder].
  • [Transliterated title] Karcinom in situ mokraćnog mjehura.
  • In this paper we have presented seven patients with carcinoma in situ of the urinary bladder, a rare intraepithelial form of transitional cell carcinoma of the urinary bladder, described first in 1952.
  • In all patients malignant cells were detected in urine sediment, and the diagnosis was proven histopathologicaly by random biopsies of the urinary bladder.
  • In five patients carcinoma in situ was associated with papillary bladder tumor, while two patients had primary carcinoma in situ.
  • In all patients a complete response was achieved after local immunotherapy or local chemotherapy.
  • After a follow-up lasting from 23 to 61 months in one patient a recurrent carcinoma in situ was diagnosed, while six patients show no signs of recurrent disease.
  • [MeSH-major] Carcinoma in Situ. Carcinoma, Transitional Cell. Urinary Bladder Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11048460.001).
  • [ISSN] 0024-3477
  • [Journal-full-title] Lijec̆nic̆ki vjesnik
  • [ISO-abbreviation] Lijec Vjesn
  • [Language] hrv
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] CROATIA
  •  go-up   go-down


5. Ren YL, Wang HY, Zhou XY, Shan BE, Yang WT, Shen L, Shi DR: [Clinical significance of Her-2/neu status in patients with uterine papillary serous carcinoma]. Zhonghua Fu Chan Ke Za Zhi; 2010 May;45(5):367-71
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical significance of Her-2/neu status in patients with uterine papillary serous carcinoma].
  • OBJECTIVE: The purpose of this study was to evaluate gene amplification by chromogenic in situ hybridization (CISH) and the protein expression of Her-2/neu gene in patients with uterine papillary serous carcinoma (UPSC) and to determine its prognostic value.
  • METHODS: Thirty-six patients with confirmed pathologic diagnosis of UPSC in Cancer Hospital of Fudan University from Jan.
  • Her-2/neu protein over-expression was significantly associated with advanced surgical stage and worse prognosis by univariate analysis (P=0.030 and P=0.002, respectively), while the multivariate analysis shown that only Her-2/neu protein over-expression and deep myometrial invasion were associated with a poor prognosis (P<0.05).
  • In 13 patients with Her-2/neu protein over-expression, the mean survival period with chemotherapy was shorter than those without chemotherapy (20 vs. 42 months, P=0.370).
  • CONCLUSION: Her-2/neu protein over-expression is significantly associated with advanced surgical stage UPSC and poor survival outcome, and might reduce the chemotherapy sensitivity.
  • [MeSH-major] Cystadenocarcinoma, Papillary / genetics. Gene Amplification. Genes, erbB-2 / genetics. Receptor, ErbB-2 / metabolism. Uterine Neoplasms / genetics
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Aged. Aged, 80 and over. Cystadenocarcinoma, Serous / genetics. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / pathology. Female. Humans. Immunohistochemistry. In Situ Hybridization / methods. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Prognosis. Retrospective Studies. Risk Factors

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20646447.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


6. Savic S, Zlobec I, Thalmann GN, Engeler D, Schmauss M, Lehmann K, Mattarelli G, Eichenberger T, Dalquen P, Spieler P, Schoenegg R, Gasser TC, Sulser T, Forster T, Zellweger T, Casella R, Bubendorf L: The prognostic value of cytology and fluorescence in situ hybridization in the follow-up of nonmuscle-invasive bladder cancer after intravesical Bacillus Calmette-Guérin therapy. Int J Cancer; 2009 Jun 15;124(12):2899-904
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The prognostic value of cytology and fluorescence in situ hybridization in the follow-up of nonmuscle-invasive bladder cancer after intravesical Bacillus Calmette-Guérin therapy.
  • Molecular markers reliably predicting failure or success of Bacillus Calmette-Guérin (BCG) in the treatment of nonmuscle-invasive urothelial bladder cancer (NMIBC) are lacking.
  • The aim of our study was to evaluate the value of cytology and chromosomal aberrations detected by fluorescence in situ hybridization (FISH) in predicting failure to BCG therapy.
  • Bladder washings collected before and after BCG instillation were analyzed by conventional cytology and by multitarget FISH assay (UroVysion, Abbott/Vysis, Des Plaines, IL) for aberrations of chromosomes 3, 7, 17 and 9p21.
  • Cytology and FISH in post-BCG bladder washings are highly interrelated and a positive result predicts failure to BCG therapy in patients with NMIBC equally well.
  • [MeSH-major] Adjuvants, Immunologic / therapeutic use. BCG Vaccine / therapeutic use. Carcinoma, Papillary / diagnosis. In Situ Hybridization, Fluorescence / utilization. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Administration, Intravesical. Adult. Aged. Aged, 80 and over. Carcinoma in Situ / diagnosis. Carcinoma in Situ / drug therapy. Carcinoma in Situ / genetics. Chromosome Aberrations. Cytodiagnosis. DNA, Neoplasm / analysis. Female. Follow-Up Studies. Humans. Incidence. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / genetics. Prognosis. Prospective Studies

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 UICC.
  • (PMID = 19230026.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / BCG Vaccine; 0 / DNA, Neoplasm
  •  go-up   go-down


7. Krishnamurthy S, Sneige N, Thompson PA, Marcy SM, Singletary SE, Cristofanilli M, Hunt KK, Kuerer HM: Nipple aspirate fluid cytology in breast carcinoma. Cancer; 2003 Apr 25;99(2):97-104
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nipple aspirate fluid cytology in breast carcinoma.
  • In the current study, the significance of cytologic findings in NAF was determined by correlating them with histopathologic findings from corresponding breast tissue.
  • METHODS: Nipple aspirate fluid was collected by breast massaging and by using a breast aspiration device from 74 women with biopsy confirmed intraductal or invasive carcinoma with or without a history of preoperative neoadjuvant chemotherapy.
  • Cytologic findings were categorized as insufficient for diagnosis (less than 10 epithelial cells), benign, mild atypia, marked atypia or suspicious, and malignant.
  • Finally, they were correlated with tissue findings.
  • RESULTS: Nipple aspirate fluid was obtained from 74 women, including 24 who had received preoperative neoadjuvant chemotherapy.
  • Patients treated with chemotherapy had fewer epithelial cells in their NAF compared with patients who were not treated with chemotherapy.
  • Thirty specimens (41%) were inadequate for diagnosis, 34 were (46%) benign, 5 (7%) were mildly atypical, 1 (1%) was markedly atypical, and 4 (5%) were malignant.
  • Of the five cases with mildly atypical cytology, three were intraductal papilloma, one was low-grade papillary intraductal carcinoma, and one was low-grade intracystic papillary carcinoma with invasion in the corresponding tissue specimen.
  • The single case with markedly atypical NAF cytology had extensive ductal carcinoma in situ (DCIS).
  • Of the four cases with malignant NAF cytology, two were extensive DCIS and two had invasive carcinoma with extensive DCIS in the breast specimen.
  • Nipple aspirate fluid is not a sensitive test for detecting invasive carcinoma of the breast.
  • Atypical cytology in NAF is associated with papillary lesions in the underlying breast.
  • [MeSH-major] Breast / cytology. Breast / pathology. Breast Neoplasms / diagnosis. Breast Neoplasms / pathology. Carcinoma, Intraductal, Noninfiltrating / diagnosis. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / pathology. Nipples

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 American Cancer Society.
  • (PMID = 12704689.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Vrabie CD, Petrescu A, Waller M: Molecular changes in superficial bladder cancer. Rom J Morphol Embryol; 2007;48(2):131-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For superficial tumors, the aim is to prevent recurrences and progression to an incurable stage, recognizing that surgical removal of the bladder (over treatment for most tumors) is curative up to a point.
  • For more invasive disease, the issue becomes how to determine which tumors can be cured with a single therapy such as surgery, and which, by virtue of a high metastatic potential, requires an integrated systemic approach to achieve cure.
  • For metastatic disease, combination chemotherapy is the standard yet, despite responses in more than 50% of cases, overall cure rates remain low, and progression has been minimal over the past few years.
  • The results showed that 70% were papillary transitional carcinomas infiltrated in lamina propria (T1), and almost 22.85% represent non-invasive papillary carcinomas (Ta); we found only five cases in Tis stage (7.15%).
  • We noticed the antibodies distribution related to stage: carcinoma in situ (Cis or Tis) high percent of p53 (69) and bcl-2 (37.5%).
  • [MeSH-major] Carcinoma in Situ / diagnosis. Carcinoma in Situ / metabolism. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / metabolism

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17641799.001).
  • [ISSN] 1220-0522
  • [Journal-full-title] Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
  • [ISO-abbreviation] Rom J Morphol Embryol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Retinoblastoma Protein; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


9. Corvera CU, Dunnican WJ, Blumgart LH, D'Angelica M: Recurrent invasive intraductal papillary mucinous carcinoma of the pancreas mimicking pott disease: review of the literature. Pancreas; 2006 Apr;32(3):321-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent invasive intraductal papillary mucinous carcinoma of the pancreas mimicking pott disease: review of the literature.
  • Specific information regarding intraductal papillary mucinous neoplasm (IPMN) recurrence is limited because most series are small and the follow-up interval is short.
  • Final pathological evaluation of the resected pancreas found a component of in situ and invasive ductal adenocarcinoma without lymph node involvement.
  • The patient did not receive postoperative chemotherapy and was monitored with transaxial imaging at regular intervals.
  • Nine years later, the patient developed a retroperitoneal psoas abscess that was misdiagnosed as tuberculous spondylitis (Pott disease) but was proven to be recurrent mucinous adenocarcinoma of pancreatic origin.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Papillary / pathology. Neoplasm Recurrence, Local / pathology. Pancreatic Neoplasms / pathology. Tuberculosis, Spinal / diagnosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16628089.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Cordon-Cardo C, Cote RJ, Sauter G: Genetic and molecular markers of urothelial premalignancy and malignancy. Scand J Urol Nephrol Suppl; 2000;(205):82-93
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These are frequently found as the sole abnormality and are often associated with particular tumors.
  • There are characteristic primary abnormalities involved in th production of low-grade/well-differentiated neoplasms, which destabilize cellular proliferation but have little effect on cellula "social" interactions or differentiation, as well as the rate of cell death or apoptosis.
  • A primary target leading to low-grade papillary superficial bladder tumors resides on chromosome 9, while p53 gene alterations are commonly seen in flat carcinoma in situ.
  • Novel approaches utilizing tissue microdissection techniques an molecular genetic assays are needed to shed further light on this subject.
  • Thus, clinical trials are underway to explore their use in specific situations, particularly in the surgical management of locally advanced disease, and to determine whether adjuvant chemotherapy in such patients may be of benefit.
  • Our knowledge of molecular alterations important in bladder cancer progression is far from complete, and further study is necessary to further elucidate cruci pathways involved in progression and therapeutic response.
  • Nevertheless, molecular alterations involving chromosome 9q and the INK4A locus in papillary superficial tumors vs changes in chromosomes 14q and 8q, p53 and RB in flat carcinoma in situ lesions may indicate a molecular basis for early events that lead to varying pathways in urothelial tumorigenesis.
  • Molecular diagnostics, particularly specific antigen expression, fluorescence in situ hybridization and microsatellite analyses, have show great promise as screening and follow-up methodologies, and may supplement urine cytology in the diagnosis and characterization of new and recurrent disease.
  • [MeSH-major] Carcinoma in Situ / genetics. Carcinoma, Transitional Cell / genetics. Genetic Markers / genetics. Precancerous Conditions / genetics. Urinary Bladder Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11144907.001).
  • [ISSN] 0300-8886
  • [Journal-full-title] Scandinavian journal of urology and nephrology. Supplementum
  • [ISO-abbreviation] Scand J Urol Nephrol Suppl
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / Genetic Markers
  • [Number-of-references] 111
  •  go-up   go-down


11. Amling CL: Diagnosis and management of superficial bladder cancer. Curr Probl Cancer; 2001 Jul-Aug;25(4):219-78
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and management of superficial bladder cancer.
  • Initial radiologic evaluation usually includes the excretory urography (intravenous pyelography), although further evaluation of the renal parenchyma with ultrasound or computed tomography scanning has been advocated by some.
  • These radiologic studies are unable to provide adequate bladder imaging, and thus cystoscopy is required for the diagnosis of bladder cancer.
  • Superficial tumors consist of papillary tumors that are mucosally confined (Ta), papillary or sessile tumors extending into the lamina propria (T1), and carcinoma in situ, which occurs as "flat" mucosal dysplasia, which can be focal, diffuse, or associated with a papillary or sessile tumor.
  • It is important to identify those tumors at risk for recurrence or progression so that adjuvant intravesical therapies can be instituted.
  • Most are given intravesically on a weekly basis, although many studies suggest that a single instillation immediately after transurethral resection may be as good as a longer course of therapy.
  • Although all of these drugs have toxicity, they usually are well tolerated.
  • Intravesical bacille Calmette-Guérin (BCG) is an immunotherapeutic agent that when given intravesically is very effective in the treatment of superficial transitional cell carcinoma.
  • Compared with controls, BCG has a 43% advantage in preventing tumor recurrence, a significantly better rate than the 16% to 21% advantage of intravesical chemotherapy.
  • In addition, BCG is particularly effective in the treatment of carcinoma in situ, eradicating it in more than 80% of cases.
  • In contrast to intravesical chemotherapy, BCG has also been shown to decrease the risk of tumor progression.
  • Unfortunately, adverse effects associated with this prolonged therapy may limit its widespread applicability.
  • In those patients at high risk in whom BCG therapy fails, intravesical interferon-alpha with or without BCG may be beneficial in some.
  • Photodynamic therapy has also been used but is limited by its toxicity.
  • In patients who progress or do not respond to intravesical therapies, cystectomy should be considered.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Biomarkers, Tumor / analysis. Carcinoma, Transitional Cell / diagnosis. Carcinoma, Transitional Cell / therapy. Immunotherapy. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / therapy
  • [MeSH-minor] ABO Blood-Group System. Administration, Intravesical. Adult. Aged. Diagnosis, Differential. Female. Hematuria / etiology. Humans. Incidence. Male. Middle Aged. Neoplasm Staging / methods. Photochemotherapy. Risk Factors. Surgical Procedures, Operative / methods. Urethra / surgery

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11514784.001).
  • [ISSN] 0147-0272
  • [Journal-full-title] Current problems in cancer
  • [ISO-abbreviation] Curr Probl Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABO Blood-Group System; 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor
  • [Number-of-references] 179
  •  go-up   go-down


12. Dalbagni G: The management of superficial bladder cancer. Nat Clin Pract Urol; 2007 May;4(5):254-60
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Transurethral resection should be done, but this procedure is prone to both overestimating and underestimating staging.
  • Data support the immediate postoperative instillation of a chemotherapeutic agent for patients with solitary, low-grade papillary tumors, whereas patients with multiple lesions might benefit from a more intensive adjuvant regimen.
  • Although the use of intravesical immunotherapy for reducing tumor progression or as maintenance therapy is controversial, bacillus Calmette-Guérin has demonstrated significant benefit for tumor prophylaxis when no obvious residual disease is present.
  • Early radical cystectomy can be beneficial and should be performed in patients with refractory T1 tumors or carcinoma in situ before progression to muscle invasion.
  • The most common intravesical chemotherapeutic agents are described as well as the impact of chemotherapy on the recurrence and progression of tumors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Transitional Cell / therapy. Cystectomy / methods. Immunotherapy / methods. Urinary Bladder Neoplasms / therapy
  • [MeSH-minor] Administration, Intravesical. BCG Vaccine / administration & dosage. Cystoscopy / methods. Female. Humans. Male. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / mortality. Neoplasm Staging. Prognosis. Randomized Controlled Trials as Topic. Risk Assessment. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17483810.001).
  • [ISSN] 1743-4289
  • [Journal-full-title] Nature clinical practice. Urology
  • [ISO-abbreviation] Nat Clin Pract Urol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCG Vaccine
  • [Number-of-references] 62
  •  go-up   go-down


13. Gaya JM, Palou J, Algaba F, Arce J, Rodríguez-Faba O, Villavicencio H: The case for conservative management in the treatment of patients with non-muscle-invasive micropapillary bladder carcinoma without carcinoma in situ. Can J Urol; 2010 Oct;17(5):5370-6
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The case for conservative management in the treatment of patients with non-muscle-invasive micropapillary bladder carcinoma without carcinoma in situ.
  • INTRODUCTION: Micropapillary carcinoma is a rare pathologic variant of urothelial cell carcinoma.
  • We assess the treatment response and disease progression in patients with micropapillary carcinoma of the bladder.
  • MATERIALS AND METHODS: The study comprised 18 patients with micropapillary carcinoma of the bladder who underwent transurethral resection of a bladder tumor and multiple random biopsies between 1997 and 2003.
  • We retrospectively analyzed treatment response and clinical and pathological cancer evolution related to cancer stage and the percentage of the micropapillary component of the cancer.
  • RESULTS: Seven of the 18 patients (38.8%) had carcinoma in situ.
  • At diagnosis, 8 of the 18 patients had non-muscle-invasive bladder cancer; 6 of these patients were treated with intravesical BCG therapy and were alive and free of disease at a median follow up of more than 5 years.
  • Seventy percent of patients with muscle-invasive disease at diagnosis had a micropapillary carcinoma component of more than 50% in transurethral resection of the bladder specimens, compared with only 25% of patients with non-muscle-invasive disease.
  • Patients treated successfully with intravesical BCG therapy had a low micropapillary carcinoma component.
  • The 5-year disease-specific survival rate was significantly lower in patients with muscle-invasive disease (30%) than in patients with non-muscle-invasive disease (87.5%) after a median follow up of 52 months (p = 0.001), and it was also significantly lower in patients with a high percentage of the micropapillary component of the carcinoma.
  • CONCLUSIONS: This retrospective study of 18 patients with micropapillary carcinoma of the bladder suggests that tumor stage and patient outcome may be related to the percentage of the micropapillary component of the carcinoma.
  • In non-muscle-invasive disease and in the absence of associated carcinoma in situ, intravesical BCG treatment may be offered when the micropapillary component of the carcinoma component is a small percentage.
  • [MeSH-major] Adjuvants, Immunologic / therapeutic use. BCG Vaccine / therapeutic use. Carcinoma in Situ / drug therapy. Carcinoma in Situ / pathology. Carcinoma, Papillary / drug therapy. Carcinoma, Papillary / pathology. Urinary Bladder Neoplasms / drug therapy. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Cystectomy. Disease Progression. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Retrospective Studies. Statistics, Nonparametric. Survival Analysis. Treatment Outcome. Urothelium / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20974029.001).
  • [ISSN] 1195-9479
  • [Journal-full-title] The Canadian journal of urology
  • [ISO-abbreviation] Can J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / BCG Vaccine
  •  go-up   go-down


14. Babjuk M, Dvorácek J: [Diagnosis and therapy of superficial tumors of the urinary bladder]. Cas Lek Cesk; 2002 Nov 22;141(23):723-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and therapy of superficial tumors of the urinary bladder].
  • [Transliterated title] Diagnostika a terapie povrchových nádorů mocového mĕchýre.
  • Among patients with bladder carcinoma, 70-80% present with superficial bladder tumors.
  • This group is composed of papillary tumors Ta, T1 and of flat nonpapillary high-grade carcinoma in situ (Tis).
  • Typical features of superficial tumors are their multifocal origin and high recurrence-rate after initial therapy.
  • The first and most important step in diagnosis and treatment of the bladder cancer is urethrocystoscopy under general or spinal anesthesia with resection of papillary lesions and biopsy of suspicious areas followed by pathologic examination of the surgical specimen.
  • The aims of intravesical therapy are treatment of Tis and prevention of recurrence and progression after TUR.
  • The most often used agents for intravesical chemotherapy are mitomycin C and adriamycin.
  • This treatment modality prolongs tumor-free interval and reduces early recurrence-rate in about 14% of patients, but cannot reduce late recurrence-rate and progression-rate.
  • BCG intravestical immunotherapy is with 73-87% response rate the most effective treatment modality in Tis.
  • It is also more effective than chemotherapy in prevention of recurrence, but is connected with more frequent side effects.
  • Radical cystectomy is considered in patients who do not respond to local therapy.
  • [MeSH-major] Carcinoma, Transitional Cell / diagnosis. Carcinoma, Transitional Cell / therapy. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12650028.001).
  • [ISSN] 0008-7335
  • [Journal-full-title] Casopís lékar̆ů c̆eských
  • [ISO-abbreviation] Cas. Lek. Cesk.
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Czech Republic
  • [Number-of-references] 50
  •  go-up   go-down


15. Ro JY, Shen SS, Lee HI, Hong EK, Lee YH, Cho NH, Jung SJ, Choi YJ, Ayala AG: Plasmacytoid transitional cell carcinoma of urinary bladder: a clinicopathologic study of 9 cases. Am J Surg Pathol; 2008 May;32(5):752-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasmacytoid transitional cell carcinoma of urinary bladder: a clinicopathologic study of 9 cases.
  • In this report, we summarized the clinicopathologic features of 9 cases of plasmacytoid transitional cell carcinoma (TCC) of the urinary bladder, a rare variant of TCC.
  • All 9 patients were men with a mean of age 64.3 years (range, 46 to 81 y).
  • Cystoscopic findings revealed a dominant solid mass with surrounding multiple papillary lesions in 6 cases and multiple masslike lesions in 3 other cases.
  • The initial diagnosis of plasmacytoid TCC was made on transurethral resection in 8 cases and cystoscopic biopsy in 1.
  • Four patients were treated by radical cystectomy with chemotherapy, 2 by radical cystectomy alone, 1 each by chemotherapy or intravesical bacillus Calmette-Guerin infusion alone, and 1 did not receive any further therapy.
  • Eight of 9 cases were associated with high-grade TCC, and transitional cell carcinoma in situ was present in 4 cases.
  • Interestingly, plasmacytoid transitional cell carcinoma in situ was noted in 1 case.
  • Morphologic recognition and distinction from other plasmacytoid malignant neoplasms is critical for its clinical management and immunohistochemical studies may be required for differential diagnosis.
  • [MeSH-major] Carcinoma, Transitional Cell / pathology. Plasma Cells / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Carcinoma in Situ / pathology. Cell Nucleus / pathology. Combined Modality Therapy. Cystoscopy. Cytoplasm / pathology. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Prognosis. Treatment Outcome

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18379419.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


16. Josephson DY, Pasin E, Stein JP: Superficial bladder cancer: part 1. Update on etiology, classification and natural history. Expert Rev Anticancer Ther; 2006 Dec;6(12):1723-34
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Superficial 'nonmuscle-invasive' bladder tumors represent a heterogeneous group of cancers, which include those that are papillary in nature and limited to the mucosa (Ta), high grade, flat and confined to the epithelium (Tis) and those that invade the submucosa or lamina propria (T1).
  • The goal in the treatment of superficial bladder cancer is twofold: reducing tumor recurrence and the subsequent need for additional therapies, such as cystoscopy, transurethral resections, intravesical therapy and the morbidity associated with these treatments; and preventing tumor progression and the subsequent need for more aggressive therapy, such as radical cystectomy.
  • The administration of intravesical chemotherapy and immunotherapy has become an important component in accomplishing these goals.
  • [MeSH-minor] Carcinogens, Environmental / adverse effects. Carcinoma in Situ / diagnosis. Carcinoma in Situ / pathology. Carcinoma, Transitional Cell / classification. Carcinoma, Transitional Cell / diagnosis. Carcinoma, Transitional Cell / etiology. Carcinoma, Transitional Cell / genetics. Carcinoma, Transitional Cell / pathology. Carcinoma, Transitional Cell / therapy. Chromosome Aberrations. Diagnosis, Differential. Disease Progression. Hematuria / etiology. Humans. Mucous Membrane / pathology. Neoplasm Invasiveness. Neoplasm Staging. Occupational Diseases / chemically induced. Papilloma / diagnosis. Papilloma / pathology. Risk Factors. Smoking / adverse effects. Urinary Tract Infections / diagnosis

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17181486.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carcinogens, Environmental
  • [Number-of-references] 124
  •  go-up   go-down


17. Xue Y, Guo XT, Liu WC: [Clinical research advancement on male breast cancer]. Ai Zheng; 2007 Oct;26(10):1148-52
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Current knowledge regarding its biology, natural history, and treatment strategies is mainly based on the research findings on female breast cancer.
  • Most cases are ductal tumors and 10% of the cases are ductal carcinoma in situ.
  • Because 90% of the patients are estrogen receptor-positive, tamoxifen is a standard adjuvant therapy, but some individuals could also benefit from chemotherapy.
  • In this article, the latest information on the epidemiology, biology, and treatment of male breast cancer is reviewed.
  • [MeSH-major] Breast Neoplasms, Male / therapy. Carcinoma, Ductal, Breast / therapy. Mastectomy / methods. Tamoxifen / therapeutic use
  • [MeSH-minor] Animals. Antineoplastic Agents, Hormonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Apoptosis Regulatory Proteins. BRCA2 Protein / genetics. Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / epidemiology. Carcinoma, Papillary / pathology. Carcinoma, Papillary / therapy. Chemotherapy, Adjuvant. Cisplatin / therapeutic use. Fluorouracil / therapeutic use. Humans. Male. Methotrexate / therapeutic use. Neoplasm Staging

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Breast Cancer, Male.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Male Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mastectomy.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17927890.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Apoptosis Regulatory Proteins; 0 / BLID protein, human; 0 / BRCA2 Protein; 0 / BRCA2 protein, human; 094ZI81Y45 / Tamoxifen; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate; CMF protocol
  • [Number-of-references] 47
  •  go-up   go-down


18. Izawa JI, Grossman HB: Localized bladder cancer. Curr Treat Options Oncol; 2000 Dec;1(5):423-32
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Transitional cell carcinoma (TCC) of the bladder makes up 90% of bladder cancers.
  • The approach to the management of localized TCC includes accurate clinical and histologic diagnosis and staging with pathologic material obtained through endoscopy.
  • Once the diagnosis of superficial TCC has been established, histologically based prognostic factors guide which therapy or combination of therapies is indicated in the management of individual patients.
  • Surgery alone (transurethral resection) is appropriate initial therapy for noninvasive papillary TCC.
  • For lamina propria invasive tumors and carcinoma in situ, intravesical immunotherapy with bacille Calmette-Guérin (BCG) is often the first line of treatment to decrease tumor recurrence and to possibly decrease progression and improve survival.
  • Intravesical chemotherapy and interferon are alternative therapies that can also decrease recurrence rates.
  • For BCG-refractory TCC, durable response rates with alternative intravesical therapies are low.
  • For superficial TCC that is refractory to endoscopic procedures and intravesical agents or for disease progression, radical cystectomy with neobladder formation or other forms of urinary diversion is the treatment of choice.
  • [MeSH-major] Carcinoma, Transitional Cell / therapy. Urinary Bladder Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. BCG Vaccine / therapeutic use. Clinical Trials as Topic. Combined Modality Therapy. Cystectomy. Diet. Endoscopy. Humans. Immunotherapy. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / therapy. Survival Rate

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 1983 Dec;130(6):1083-6 [6644886.001]
  • [Cites] N Engl J Med. 1992 Mar 12;326(11):737-40 [1445507.001]
  • [Cites] Urol Clin North Am. 2000 Feb;27(1):137-46, [10696252.001]
  • [Cites] J Urol. 1999 Apr;161(4):1133-5; discussion 1135-6 [10081854.001]
  • [Cites] Urology. 2000 Feb;55(2):161-8 [10688071.001]
  • [Cites] Cancer Res. 1998 Aug 15;58(16):3603-10 [9721868.001]
  • [Cites] J Clin Oncol. 1995 Jun;13(6):1404-8 [7751885.001]
  • [Cites] Urol Clin North Am. 2000 Feb;27(1):103-13, ix [10696249.001]
  • [Cites] J Urol. 1995 Mar;153(3 Pt 2):934-41 [7853578.001]
  • [Cites] J Urol. 1996 Sep;156(3):962-6 [8709374.001]
  • [Cites] Urol Clin North Am. 2000 Feb;27(1):15-24, vii-viii [10696241.001]
  • [Cites] Urol Clin North Am. 2000 Feb;27(1):1-13, vii [10696240.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1298-301 [9552029.001]
  • [Cites] J Urol. 2000 Apr;163(4):1124-9 [10737480.001]
  • [Cites] J Clin Oncol. 1994 Jan;12 (1):7-13 [8270987.001]
  • [Cites] BJU Int. 2000 Mar;85(5):599-610 [10735935.001]
  • [Cites] Br J Urol. 1998 May;81(5):692-8 [9634043.001]
  • [Cites] Urol Clin North Am. 1992 Aug;19(3):455-65 [1636230.001]
  • [Cites] J Urol. 1998 Jun;159(6):1793-801 [9598463.001]
  • [Cites] J Urol. 1994 Jan;151(1):21-6 [8254816.001]
  • [Cites] Urol Clin North Am. 2000 Feb;27(1):171-8, xi [10696256.001]
  • [Cites] N Engl J Med. 1999 May 6;340(18):1390-7 [10228189.001]
  • [Cites] J Urol. 1999 Apr;161(4):1120-3 [10081851.001]
  • [Cites] CA Cancer J Clin. 2000 Jan-Feb;50(1):7-33 [10735013.001]
  • [Cites] J Natl Cancer Inst. 1993 Jul 21;85(14):1159-64 [8320745.001]
  • [Cites] J Urol. 1986 May;135(5):920-2 [3959241.001]
  • [Cites] Urology. 1997 Oct;50(4):529-35 [9338727.001]
  • [Cites] CA Cancer J Clin. 1998 Sep-Oct;48(5):269-84 [9742894.001]
  • [Cites] Semin Surg Oncol. 1997 Sep-Oct;13(5):291-8 [9259084.001]
  • [Cites] Urol Clin North Am. 2000 Feb;27(1):125-35, x [10696251.001]
  • [Cites] Eur Urol. 1995;28(4):284-90 [8575494.001]
  • [Cites] J Urol. 1999 Aug;162(2):445-50; discussion 450-1 [10411054.001]
  • [Cites] Cancer. 1999 Jun 25;87(3):118-28 [10385442.001]
  • (PMID = 12057150.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / BCG Vaccine
  • [Number-of-references] 34
  •  go-up   go-down


19. Levi AW, Potter SR, Schoenberg MP, Epstein JI: Clinical significance of denuded urothelium in bladder biopsy. J Urol; 2001 Aug;166(2):457-60
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We correlated the pertinent clinical features of patients with denuded bladder biopsies and/or specific pathological features of denuded bladder biopsy specimens with patient outcome in regard to bladder lesions to help predict the subsequent likelihood of diagnosing bladder carcinoma in a patient with a nondiagnostic denuded biopsy.
  • In remainder there were flat carcinoma in situ with or without other tumors (26%), high (20%) and low (14%) grade papillary tumors without carcinoma in situ and miscellaneous conditions (6%).
  • Overall 31% of patients were diagnosed with carcinoma in situ within 24 months (median 5.5) after the denuded specimen was obtained.
  • Parameters that did not correlate with the subsequent diagnosis of carcinoma in situ included cystoscopic impression, history of intravesical chemotherapy, sex, age, tissue inflammation, percent of tissue fragments with any denudation, number of denuded tissue fragments and percent of overall denuded epithelium.
  • A history of carcinoma in situ before denuded biopsy predicted a diagnosis of carcinoma in situ within 24 months after denuded biopsy in 54% of patients in contrast to 19% of those without a history of carcinoma in situ (p = 0.03).
  • Factoring in a history of other bladder tumor types in various combinations did not predict carcinoma in situ after denuded biopsy.
  • Carcinoma in situ developed within 24 months in 45% of patients in whom the denuded specimen was obtained by cold cup biopsy in contrast to none who underwent hot wire loop biopsy (p = 0.007).
  • Cold cup biopsy and a history of carcinoma in situ were independently predictive.
  • Carcinoma in situ developed within 24 months in 75% of patients with a history of that condition and a subsequent cold cup biopsy showing denuded epithelium.
  • However, only 29% of those who underwent cold cup biopsy and had no history of carcinoma in situ were diagnosed with carcinoma in situ.
  • CONCLUSIONS: In bladder biopsies obtained by a hot wire loop denudation most likely results from thermal injury when there is a low risk of subsequent carcinoma in situ.
  • When the denuded biopsy sample was obtained by cold cup biopsy, particularly when associated with a history of carcinoma in situ, most cases represent neoplastic cell denudation and a high risk for subsequent carcinoma in situ.
  • [MeSH-major] Biopsy. Carcinoma in Situ / pathology. Urinary Bladder / pathology. Urinary Bladder Neoplasms / pathology. Urothelium / pathology

  • MedlinePlus Health Information. consumer health - Biopsy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11458047.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Fukunaga M, Fujiwara Y, Naito Z: Hepatoid carcinoma with serous component of the fallopian tube: a case report with immunohistochemical and ultrastructural studies. Int J Gynecol Pathol; 2006 Jul;25(3):233-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatoid carcinoma with serous component of the fallopian tube: a case report with immunohistochemical and ultrastructural studies.
  • A very rare case of hepatoid carcinoma with serous component arising in the fallopian tube of a 79-year-old woman is presented.
  • The tumor was composed of hepatoid carcinoma (90%) and serous carcinoma (10%) components.
  • The hepatoid carcinoma was histologically characterized by a proliferation of round to polygonal cells arranged in a trabecular, tubular, sinusoidal, papillary, or solid pattern.
  • The serous component in the fallopian tube also showed in situ lesions.
  • Immunohistochemically, the hepatoid carcinoma was positive for alpha-fetoprotein, polyclonal carcinoembryonic antigen (CEA), hepatocyte paraffin 1, albumin, epithelial membrane antigen, and cytokeratin (CAM5.2).
  • Ultrastructurally, the cytoplasm contained abundant ribosomes, moderate amounts of mitochondria, and rough endoplasmic reticulum that developed into a meshwork and contained mitochondria within it.
  • The association with serous carcinoma indicates mullerian origin rather than germ cell origin.
  • The patient received chemotherapy and was alive without disease at 10 months after surgery.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Fallopian Tube Neoplasms / pathology
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Keratins / analysis. Microscopy, Electron, Transmission. alpha-Fetoproteins / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16810059.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / alpha-Fetoproteins; 68238-35-7 / Keratins
  •  go-up   go-down


21. Berglund RK, Savage CJ, Vora KC, Kurta JM, Cronin AM: An analysis of the effect of statin use on the efficacy of bacillus calmette-guerin treatment for transitional cell carcinoma of the bladder. J Urol; 2008 Oct;180(4):1297-300; discussion 1300
MedlinePlus Health Information. consumer health - Statins.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An analysis of the effect of statin use on the efficacy of bacillus calmette-guerin treatment for transitional cell carcinoma of the bladder.
  • PURPOSE: Bacillus Calmette-Guerin is an effective immunotherapy for carcinoma in situ of the bladder and it reduces recurrence from resected papillary transitional cell carcinoma of the bladder.
  • Many patients receiving bacillus Calmette-Guerin therapy are concurrently taking statin agents, which have known immunomodulatory properties and may alter the performance of bacillus Calmette-Guerin.
  • Some data have suggested that patients taking a statin while on bacillus Calmette-Guerin therapy experience reduced clinical efficacy.
  • Time to recurrence and progression to surgery were compared between those taking and those not taking a statin by Kaplan-Meier methods and multivariable Cox regression controlling for stage and grade.
  • RESULTS: There were 245 (26%) patients taking a statin before bacillus Calmette-Guerin therapy and 707 not on statin therapy (74%).
  • Median time to recurrence was similar between those who did and those who did not use a statin.
  • On multivariable analysis statin use was not significantly associated with recurrence (hazard ratio 1.04; 95% CI 0.81, 1.34; p = 0.7) or progression to surgery (hazard ratio 0.77; 95% CI 0.52, 1.13; p = 0.17) after bacillus Calmette-Guerin therapy.
  • CONCLUSIONS: This retrospective study in a large cohort of patients showed no statistically significant association between statin use and recurrence or progression to open surgery in patients treated with bacillus Calmette-Guerin for transitional cell carcinoma of the bladder.
  • Based on these data patients should not be discouraged from taking statins while undergoing bacillus Calmette-Guerin treatment.
  • [MeSH-major] BCG Vaccine / therapeutic use. Carcinoma, Transitional Cell / drug therapy. Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use. Neoplasm Recurrence, Local / diagnosis. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Administration, Intravesical. Aged. Aged, 80 and over. Cohort Studies. Disease Progression. Drug Therapy, Combination. Evaluation Studies as Topic. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Prognosis. Proportional Hazards Models. Reference Values. Retrospective Studies. Risk Assessment. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18707737.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCG Vaccine; 0 / Hydroxymethylglutaryl-CoA Reductase Inhibitors
  •  go-up   go-down


22. Holmäng S, Thomsen J, Johansson SL: Micropapillary carcinoma of the renal pelvis and ureter. J Urol; 2006 Feb;175(2):463-6; discussion 466-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Micropapillary carcinoma of the renal pelvis and ureter.
  • MATERIALS AND METHODS: A clinical and histopathological review was performed in 943 patients with a neoplasm in the renal pelvis or ureter, diagnosed between 1971 and 1998.
  • Median patient age at diagnosis was 69 years (range 54 to 88) and the male-to-female ratio was 17:9.
  • Carcinoma in situ was identified in 64% of cases and vascular invasion was present in 81%.
  • Stage for stage the prognosis is not different from that in nonMPC urothelial cell carcinoma.
  • However, radiotherapy and systemic chemotherapy appear to be ineffective.
  • [MeSH-major] Carcinoma, Papillary. Kidney Neoplasms. Kidney Pelvis. Ureteral Neoplasms

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16406972.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


23. Losa A, Hurle R, Lembo A: Low dose bacillus Calmette-Guerin for carcinoma in situ of the bladder: long-term results. J Urol; 2000 Jan;163(1):68-71; discussion 71-2
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low dose bacillus Calmette-Guerin for carcinoma in situ of the bladder: long-term results.
  • PURPOSE: Bacillus Calmette-Guerin (BCG) is standard treatment for carcinoma in situ of the bladder.
  • MATERIALS AND METHODS: From January 1987 to January 1995, 70 consecutive patients with primary or secondary carcinoma in situ with or without concomitant solitary or multifocal papillary tumor were treated with weekly instillations of 75 mg.
  • Pasteur strain BCG for 6 weeks after histological diagnosis.
  • Mean time was 18 months (range 6 to 69) to treatment failure and 13 months (range 7 to 53) to progression.
  • The risk of treatment failure was significantly greater for carcinoma in situ associated with stage T1 papillary tumor (p = 0.0001) or severe dysplasia (p = 0.0005), and the risk of disease progression was significantly greater for carcinoma in situ associated with stage T1 papillary tumor (p = 0.0001).
  • The drug was well tolerated with few side effects.
  • CONCLUSIONS: Intravesical BCG is the best available conservative therapy for patients with carcinoma in situ of the bladder.
  • Low dose BCG is similarly effective, with a lower incidence of side effects and long lasting positive outcome.
  • [MeSH-major] Adjuvants, Immunologic / administration & dosage. BCG Vaccine / administration & dosage. Carcinoma in Situ / drug therapy. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Male. Middle Aged. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Urol. 2000 Jan;163(1):79-80 [10604318.001]
  • (PMID = 10604316.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / BCG Vaccine
  •  go-up   go-down


24. Jocham D, von Wietersheim J, Pflüger H, Steiner H, Doehn C, Büttner H, Böhle A, Kausch I: [BCG versus photodynamic therapy (PDT) for nonmuscle invasive bladder cancer-a multicentre clinical phase III study]. Aktuelle Urol; 2009 Mar;40(2):91-9
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [BCG versus photodynamic therapy (PDT) for nonmuscle invasive bladder cancer-a multicentre clinical phase III study].
  • [Transliterated title] BCG versus Photodynamische Therapie (PDT) beim nicht muskelinvasiven Harnblasenkarzinom--eine multizentrische Phase-III-Studie.
  • PURPOSE: This multicentre phase III study was designed to compare the efficacy of Bacillus Calmette Guérin (BCG) instillations and photodynamic therapy (PDT) in the treatment of patients with intermediate and high-risk nonmuscle invasive bladder cancer.
  • MATERIAL AND METHODS: Inclusion criteria were multifocal pTaG1-G2 tumours, recurrent pTaG1-2 tumours, pTa / 1G3 tumours, and primary or recurrent carcinoma in situ (CIS).
  • All patients were centrally randomised after transurethral resection (TUR) to receive BCG induction and maintenance therapy or a single PDT with Photofrin.
  • Kaplan-Meier curves demonstrated no statistically significant differences between the two therapy arms with respect to recurrence-free survival after randomisation (p = 0.4598).
  • CONCLUSIONS: A single PDT with Photofrin(R) in intermediate and high-risk nonmuscle invasive bladder cancer patients could not be shown to be superior to BCG maintenance therapy.
  • [MeSH-major] BCG Vaccine / therapeutic use. Carcinoma in Situ / drug therapy. Carcinoma, Papillary / drug therapy. Hematoporphyrin Photoradiation. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Administration, Intravesical. Adult. Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Cystoscopy. Disease Progression. Disease-Free Survival. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / mortality. Neoplasm Staging. Quality of Life

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19214951.001).
  • [ISSN] 1438-8820
  • [Journal-full-title] Aktuelle Urologie
  • [ISO-abbreviation] Aktuelle Urol
  • [Language] ger
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; English Abstract; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / BCG Vaccine
  •  go-up   go-down


25. Barberis M, Pellegrini C, Cannone M, Arizzi C, Coggi G, Bosari S: Quantitative PCR and HER2 testing in breast cancer: a technical and cost-effectiveness analysis. Am J Clin Pathol; 2008 Apr;129(4):563-70
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We evaluated 44 frozen and 55 formalin-fixed paraffin-embedded (FFPE) breast carcinoma specimens by Q-RT-PCR, immunohistochemical analysis, and fluorescent in situ hybridization (FISH).
  • Immunohistochemical and FISH analyses were performed on individual slides and on tissue microarray.
  • Cost analysis documented the advantage of Q-RT-PCR in all US Food and Drug Administration-approved assays.
  • Our data support the use of Q-RT-PCR for testing breast cancer specimens to select patients for HER2 inhibitory therapy.
  • [MeSH-major] Breast Neoplasms / genetics. Carcinoma, Ductal, Breast / genetics. Receptor, ErbB-2 / genetics. Reverse Transcriptase Polymerase Chain Reaction / economics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Apocrine Glands / metabolism. Apocrine Glands / pathology. Carcinoma, Lobular / diagnosis. Carcinoma, Lobular / genetics. Carcinoma, Lobular / metabolism. Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / genetics. Carcinoma, Papillary / metabolism. Cost-Benefit Analysis. Female. Gene Expression. Humans. In Situ Hybridization, Fluorescence / economics. In Situ Hybridization, Fluorescence / methods. Middle Aged. RNA, Messenger / analysis. RNA, Neoplasm / analysis. Sweat Gland Neoplasms / genetics. Sweat Gland Neoplasms / metabolism. Sweat Gland Neoplasms / pathology. Tissue Array Analysis / economics. Tissue Array Analysis / methods

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18343783.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / RNA, Neoplasm; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down






Advertisement